MedTrace Logo

Study Comparing Treatment Effectiveness of Guideline Indicated APT for ACS in Patients With CKD

NCT03150667 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2018-05-25

No results posted yet for this study

Summary

To compare clinical outcomes in patients with chronic kidney disease (CKD) presenting with an acute coronary syndrome (ACS) treated with clopidogrel or ticagrelor (both FDA approved and guideline indicated drugs for treating these patients upstream managed medically or with coronary revascularization).

Conditions

  • Chronic Kidney Diseases
  • Acute Coronary Syndrome

Interventions

DRUG

Ticagrelor

Ticagrelor in patients with CKD presenting with ACS.

DRUG

Clopidogrel

Clopidogrel in patients with CKD presenting with ACS.

Sponsors & Collaborators

  • North Texas Veterans Healthcare System

    lead FED

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-10
Primary Completion
2019-04-30
Completion
2020-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03150667 on ClinicalTrials.gov